• 1
    Bishop MR,Alyea EPIII,Cairo MS,Falkenburg JH,June CH,Kröger N,Little RF,Miller JS,Pavletic SZ,Porter D,Riddell SR,van Besien K,Wayne AS,Weisdorf DJ,Wu R,Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 563564.
  • 2
    Bishop MR,Alyea EPIII,Cairo MS,Falkenburg JH,June CH,Kröger N,Little RF,Miller JS,Pavletic SZ,Porter DL,Riddell SR,van Besien K,Wayne AS,Weisdorf DJ,Wu RS,Giralt S. National Cancer Institute's First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011; 17: 443454.
  • 3
    Rihani R,Bazzeh F,Faqih N,Sultan I. Secondary hematopoietic malignancies in survivors of childhood cancer: An analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 2010; 116: 43854394.
  • 4
    Bhatia S,Krailo MD,Chen Z,Burden L,Askin FB,Dickman PS,Grier HE,Link MP,Meyers PA,Perlman EJ,Rausen AR,Robison LL,Vietti TJ,Miser JS. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007; 109: 4651.
  • 5
    Miser JS,Goldsby RE,Chen Z,Krailo MD,Tarbell NJ,Link MP,Fryer CJ,Pritchard DJ,Gebhardt MC,Dickman PS,Perlman EJ,Meyers PA,Donaldson SS,Moore SG,Rausen AR,Vietti TJ,Grier HE. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—A report from the Children's Oncology Group. Pediatr Blood Cancer 2007; 49: 894900.
  • 6
    Baird K,Fry TJ,Steinberg SM,Bishop MR,Fowler DH,Delbrook CP,Humphrey JL,Rager A,Richards K,Wayne AS,Mackall CL. Reduced intensity allogeneic stem cell transplantation in children and young adults with ultra-high risk pediatric sarcomas. Biol Blood Marrow Transplant 2011. [epub ahead of print]
  • 7
    Socie G,Curtis RE,Deeg HJ,Sobocinski KA,Filipovich AH,Travis LB,Sullivan KM,Rowlings PA,Kingma DW,Banks PM,Travis WD,Witherspoon RP,Sanders J,Jaffe ES,Horowitz MM. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348357.
  • 8
    Rizzo JD,Curtis RE,Socie G,Sobocinski KA,Gilbert E,Landgren O,Travis LB,Travis WD,Flowers ME,Friedman DL,Horowitz MM,Wingard JR,Deeg HJ. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 11751183.
  • 9
    Cohen A,Rovelli A,Merlo DF,van Lint MT,Lanino E,Bresters D,Ceppi M,Bocchini V,Tichelli A,Socie G. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: An EBMT late effects working party study. J Clin Oncol 2007; 25: 24492454.
  • 10
    Baker KS,DeFor TE,Burns LJ,Ramsay NK,Neglia JP,Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003; 21: 13521358.
  • 11
    Pedersen-Bjergaard J,Andersen MK,Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95: 32733279.
  • 12
    Kollmannsberger C,Hartmann JT,Kanz L,Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124: 207214.
  • 13
    Dufour C,Da Costa L,Auger N,Jullien M,Bhangoo R,Grill J. Treatment-related myelodysplastic syndrome after temozolomide use in a child: First report. J Pediatr Hematol Oncol 2008; 30: 857859.
  • 14
    Noronha V,Berliner N,Ballen KK,Lacy J,Kracher J,Baehring J,Henson JW. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neuro Oncol 2006; 8: 280283.
  • 15
    Natelson EA,Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol 2010; 2010: 760402.
  • 16
    Carney DA,Westerman DA,Tam CS,Milner A,Prince HM,Kenealy M,Wolf M,Januszewicz EH,Ritchie D,Came N,Seymour JF. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24: 20562062.
  • 17
    Germing U,Strupp C,Kuendgen A,Isa S,Knipp S,Hildebrandt B,Giagounidis A,Aul C,Gattermann N,Haas R. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006; 91: 15961604.
  • 18
    Greenberg PL,Attar E,Bennett JM,Bloomfield CD,De Castro CM,Deeg HJ,Foran JM,Gaensler K,Garcia-Manero G,Gore SD,Head D,Komrokji R,Maness LJ,Millenson M,Nimer SD,O'Donnell MR,Schroeder MA,Shami PJ,Stone RM,Thompson JE,Westervelt P. Myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9: 3056.
  • 19
    Brunning RD,Orazi A,Germing U,LeBeau MM,Porwit A,Baumann I,Vardiman JW,Hellstrom-Lindberg E. Myelodysplastic syndromes/neoplasm, overview. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. World Health Organization, International Agency for Research on Cancer (IARC)m. Lyon, 2008.
  • 20
    Hasle H,Niemeyer CM,Chessells JM,Baumann I,Bennett JM,Kerndrup G,Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277282.
  • 21
    Rizzo JD,Wingard JR,Tichelli A,Lee SJ,Van Lint MT,Burns LJ,Davies SM,Ferrara JL,Socie G. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: Joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138151.
  • 22
    van Marion AM,Thiele J,Kvasnicka HM,van den Tweel JG. Morphology of the bone marrow after stem cell transplantation. Histopathology 2006; 48: 329342.
  • 23
    Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 490498.
  • 24
    Mauritzson N,Albin M,Rylander L,Billstrom R,Ahlgren T,Mikoczy Z,Bjork J,Stromberg U,Nilsson PG,Mitelman F,Hagmar L,Johansson B. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002; 16: 23662378.
  • 25
    Pedersen-Bjergaard J,Andersen MK,Andersen MT,Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240248.
  • 26
    Qian Z,Joslin JM,Tennant TR,Reshmi SC,Young DJ,Stoddart A,Larson RA,Le Beau MM. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact 2010; 184: 5057.
  • 27
    Tiu RV,Gondek LP,O'Keefe CL,Elson P,Huh J,Mohamedali A,Kulasekararaj A,Advani AS,Paquette R,List AF,Sekeres MA,McDevitt MA,Mufti GJ,Maciejewski JP. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 45524560.
  • 28
    Fuehrer M,Gerusel-Bleck M,Konstantopoulos N,Bender-Goetze C,Walther JU. FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children. Int J Mol Med 2005; 15: 291297.
  • 29
    Valent P,Horny HP,Bennett JM,Fonatsch C,Germing U,Greenberg P,Haferlach T,Haase D,Kolb HJ,Krieger O,Loken M,van de Loosdrecht A,Ogata K,Orfao A,Pfeilstocker M,Ruter B,Sperr WR,Stauder R,Wells DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727736.
  • 30
    Diez-Campelo M,Perez-Simon JA,Perez J,Alcoceba M,Richtmon J,Vidriales B,San Miguel J. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009; 84: 149152.
  • 31
    Kröger N,Bacher U,Bader P,Bottcher S,Borowitz MJ,Dreger P,Khouri I,Macapinlac HA,Olavarria E,Radich J,Stock W,Vose JM,Weisdorf D,Willasch A,Giralt S,Bishop MR,Wayne AS. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the Committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010; 16: 11871211.
  • 32
    Langemeijer SM,Kuiper RP,Berends M,Knops R,Aslanyan MG,Massop M,Stevens-Linders E,van Hoogen P,van Kessel AG,Raymakers RA,Kamping EJ,Verhoef GE,Verburgh E,Hagemeijer A,Vandenberghe P,de Witte T,van der Reijden BA,Jansen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838842.
  • 33
    Dicker F,Haferlach C,Sundermann J,Wendland N,Weiss T,Kern W,Haferlach T,Schnittger S. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 15281532.
  • 34
    Abeliovich D,Yehuda O,Nagler A,Lerer I,Ben-Neriah S,Amar A,Or R. Predominant 45,X,—Y karyotype in donor cells after allogeneic BMT: Cytogenetic and molecular analysis. Cancer Genet Cytogenet 1996; 86: 17.
  • 35
    Wiseman DH. Donor cell leukemia: A review. Biol Blood Marrow Transplant 2011; 17: 771789.
  • 36
    Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: New methods and markers. Am J Pharmacogenomics 2004; 4: 177187.
  • 37
    Khan F,Agarwal A,Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: New variations on an old theme. Bone Marrow Transplant 2004; 34: 112.
  • 38
    Ruiz-Arguelles GJ,Ruiz-Arguelles A,Garces-Eisele J. Donor cell leukemia: A critical review. Leuk Lymphoma 2007; 48: 2538.
  • 39
    Pavletic SZ,Kumar S,Mohty M,de Lima M,Foran JM,Pasquini M,Zhang MJ,Giralt S,Bishop MR,Weisdorf D. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the Committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 871890.
  • 40
    Luger SM,Ringden O,Zhang MJ,Perez WS,Bishop MR,Bornhauser M,Bredeson CN,Cairo MS,Copelan EA,Gale RP,Giralt SA,Gulbas Z,Gupta V,Hale GA,Lazarus HM,Lewis VA,Lill MC,McCarthy PL,Weisdorf DJ,Pulsipher MA. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012;47:203–211.
  • 41
    Crow J,Youens K,Michalowski S,Perrine G,Emhart C,Johnson F,Gerling A,Kurtzberg J,Goodman BK,Sebastian S,Rehder CW,Datto MB. Donor cell leukemia in umbilical cord blood transplant patients: A case study and literature review highlighting the importance of molecular engraftment analysis. J Mol Diagn 2010; 12: 530537.
  • 42
    Cooley LD,Sears DA,Udden MM,Harrison WR,Baker KR. Donor cell leukemia: Report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000; 63: 4653.
  • 43
    Reichard KK,Zhang QY,Sanchez L,Hozier J,Viswanatha D,Foucar K. Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: Case report and review of the literature. Am J Hematol 2006; 81: 178185.
  • 44
    Hertenstein B,Hambach L,Bacigalupo A,Schmitz N,McCann S,Slavin S,Gratwohl A,Ferrant A,Elmaagacli A,Schwertfeger R,Locasciulli A,Zander A,Bornhauser M,Niederwieser D,Ruutu T. Development of leukemia in donor cells after allogeneic stem cell transplantation—A survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005; 90: 969975.
  • 45
    Komrokji R,Ifthikharuddin JJ,Felgar RE,Abboud CN,Wedow LA,Connaughton A,Bennett JM. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: Case report and literature review. Am J Hematol 2004; 76: 389394.
  • 46
    Sala Torra O,Loeb KR. Donor cell-derived leukemia and myelodysplastic neoplasm: Unique forms of leukemia. Am J Clin Pathol 2011; 135: 501504.
  • 47
    Wang E,Hutchinson CB,Huang Q,Lu CM,Crow J,Wang FF,Sebastian S,Rehder C,Lagoo A,Horwitz M,Rizzieri D,Yu J,Goodman B,Datto M,Buckley P. Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: A clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol 2011; 135: 525540.
  • 48
    Haltrich I,Muller J,Szabo J,Kovacs G,Koos R,Poros A,Dobos M,Fekete G. Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. Cancer Genet Cytogenet 2003; 142: 124128.
  • 49
    Shekhter-Levin S,Bloom EJ,Swerdlow SH,Sherer ME,Wald N,Gollin SM. Acquired monosomy 7 in donor cells in a patient treated for acute lymphoblastic leukemia with bone marrow transplantation. Cancer Genet Cytogenet 1997; 95: 190197.
  • 50
    Komeno Y,Kanda Y,Kandabashi K,Kawazu M,Goyama S,Takeshita M,Nannya Y,Niino M,Nakamoto T,Kurokawa M,Tsujino S,Ogawa S,Aoki K,Chiba S,Motokura T,Hirai H. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. Am J Hematol 2003; 72: 220222.
  • 51
    Lang Z,Dinndorf P,Ladisch S,Bayever E,Reaman G. Chromosomal transformation in donor cells following allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 33: 12531256.
  • 52
    Orciuolo E,Azzara A,Bandini G,Galimberti S,Bonifazi F,Fazzi R,Petrini M. Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. Bone Marrow Transplant 2004; 33: 859861.
  • 53
    Boulton-Jones R,Parker A,Hepburn M,Bowen DT. Secondary myelodysplasia of donor cell origin following nonmyeloablative sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 471472.
  • 54
    Kraut L,Trebeljahr G,Thiele B,Fauser AA. Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph+ chronic myeloid leukemia. Bone Marrow Transplant 2005; 36: 737.
  • 55
    Beck C,Humpe A,Harder S,Schmid M,Horst HA. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: Two very rare conditions in one patient. Ann Hematol 2005; 84: 616618.
  • 56
    Sala-Torra O,Hanna C,Loken MR,Flowers ME,Maris M,Ladne PA,Mason JR,Senitzer D,Rodriguez R,Forman SJ,Deeg HJ,Radich JP. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 511517.
  • 57
    Hashino S,Fujisawa F,Kondo T,Imamura M,Sato K,Torimoto Y,Kohgo Y,Kimura K,Furukawa H,Todo S,Asaka M. Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. Int J Hematol 2006; 84: 363366.
  • 58
    Fraser CJ,Hirsch BA,Dayton V,Creer MH,Neglia JP,Wagner JE,Baker KS. First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood 2005; 106: 43774380.
  • 59
    Brunstein CG,Hirsch BA,Hammerschmidt D,McGlennen RC,Nguyen PL,Verfaillie CM. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2002; 29: 9991003.
  • 60
    Lowsky R,Fyles G,Minden M,Lipton J,Meharchand J,Tejpar I,Zipursky A,Messner H. Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. Br J Haematol 1996; 93: 163165.
  • 61
    Gopcsa L,Barta A,Banyai A,Konya M,Pajor L,Foldi J,Paloczi K. Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2002; 29: 449452.
  • 62
    Bielorai B,Deeg HJ,Weintraub M,Neumann Y,Rosner E,Amariglio N,Rechavi G,Toren A. B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation. Bone Marrow Transplant 2003; 31: 931934.
  • 63
    Daly AS,Kamel-Reid S,Lipton JH,Messner HA,Kiss TL,Chun K,Busque L,Chang H. Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leuk Res 2004; 28: 11071111.
  • 64
    Stevens JM,Syndercombe-Court D,Oakervee HE,McCloskey D,Jenner MJ,Gribben JG,Cavenagh JD. Development of original donor cell leukemia after successful engraftment from a second donor. Blood 2007; 110: 46214622.
  • 65
    Aizawa S,Nakano M,Iwase O,Yaguchi M,Hiramoto M,Hoshi H,Nabeshima R,Shima D,Handa H,Toyama K. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23: 239246.
  • 66
    Deeg HJ. Marrow stroma in MDS: Culprit or bystander? Leuk Res 2002; 26: 687688.
  • 67
    Raaijmakers MH,Mukherjee S,Guo S,Zhang S,Kobayashi T,Schoonmaker JA,Ebert BL,Al-Shahrour F,Hasserjian RP,Scadden EO,Aung Z,Matza M,Merkenschlager M,Lin C,Rommens JM,Scadden DT. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852857.
  • 68
    Leguit RJ,van den Berg H,Buijs A,Mellink C,Bierings M. Donor-cell MDS in a 12-year-old girl 3 years after allogeneic hematopoietic SCT for MDS, both with a t(3;3)(q21;q26) cytogenetic aberration. Bone Marrow Transplant 2011;46:908910.
  • 69
    Menes M,Vakiani E,Keller CE,Ho EK,Colovai A,Nichols G,Diuguid D,Mears JG,Murty VV,Alobeid B,Bhagat G. The spectrum of myelodysplastic syndromes post-solid organ transplantation: A single institutional experience. Leuk Res 2007; 31: 5965.
  • 70
    Fenaux P,Mufti GJ,Hellstrom-Lindberg E,Santini V,Finelli C,Giagounidis A,Schoch R,Gattermann N,Sanz G,List A,Gore SD,Seymour JF,Bennett JM,Byrd J,Backstrom J,Zimmerman L,McKenzie D,Beach C,Silverman LR. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223232.
  • 71
    Itzykson R,Thepot S,Quesnel B,Dreyfus F,Beyne-Rauzy O,Turlure P,Vey N,Recher C,Dartigeas C,Legros L,Delaunay J,Salanoubat C,Visanica S,Stamatoullas A,Isnard F,Marfaing-Koka A,de Botton S,Chelghoum Y,Taksin AL,Plantier I,Ame S,Boehrer S,Gardin C,Beach CL,Ades L,Fenaux P. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403411.
  • 72
    Steensma DP,Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 389406.
  • 73
    Graef T,Kuendgen A,Fenk R,Zohren F,Haas R,Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007; 31: 257259.
  • 74
    Campregher PV,Gooley T,Scott BL,Moravec C,Sandmaier B,Martin PJ,Deeg HJ,Warren EH,Flowers ME. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 965971.
  • 75
    Jacobs JF,Brons PP,Simons A,van der Reijden BA,Hoogerbrugge PM. Therapy-related, donor-derived AML responding to a second allogeneic BMT. Bone Marrow Transplant 2007; 40: 499500.
  • 76
    Litzow MR,Tarima S,Perez WS,Bolwell BJ,Cairo MS,Camitta BM,Cutler CS,de Lima M,Dipersio JF,Gale RP,Keating A,Lazarus HM,Luger S,Marks DI,Maziarz RT,McCarthy PL,Pasquini MC,Phillips GL,Rizzo JD,Sierra J,Tallman MS,Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010;115:18501857.
  • 77
    Hasle H,Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol 2011;154:185195.
  • 78
    Kröger N,Brand R,van Biezen A,Cahn JY,Slavin S,Blaise D,Sierra J,Zander A,Niederwieser D,de Witte T. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37: 183189.
  • 79
    de Witte T,Oosterveld M,Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev 2007; 21: 4959.
  • 80
    List A,Dewald G,Bennett J,Giagounidis A,Raza A,Feldman E,Powell B,Greenberg P,Thomas D,Stone R,Reeder C,Wride K,Patin J,Schmidt M,Zeldis J,Knight R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 14561465.
  • 81
    Ades L,Boehrer S,Prebet T,Beyne-Rauzy O,Legros L,Ravoet C,Dreyfus F,Stamatoullas A,Chaury MP,Delaunay J,Laurent G,Vey N,Burcheri S,Mbida RM,Hoarau N,Gardin C,Fenaux P. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: Results of a phase 2 study. Blood 2009; 113: 39473952.
  • 82
    Jabbour E,Giralt S,Kantarjian H,Garcia-Manero G,Jagasia M,Kebriaei P,de Padua L,Shpall EJ,Champlin R,de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115: 18991905.
  • 83
    de Lima M,Giralt S,Thall PF,de Padua Silva L,Jones RB,Komanduri K,Braun TM,Nguyen HQ,Champlin R,Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010; 116: 54205431.
  • 84
    Bartenstein M,Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 2010; 24: 407422.
  • 85
    Ballen KK,Gilliland DG,Guinan EC,Hsieh CC,Parsons SK,Rimm IJ,Ferrara JL,Bierer BE,Weinstein HJ,Antin JH. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20: 737743.
  • 86
    Hale GA,Heslop HE,Bowman LC,Rochester RA,Pui CH,Brenner MK,Krance RA. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999; 24: 735739.
  • 87
    Kröger N,Brand R,van Biezen A,Zander A,Dierlamm J,Niederwieser D,Devergie A,Ruutu T,Cornish J,Ljungman P,Gratwohl A,Cordonnier C,Beelen D,Deconinck E,Symeonidis A,de Witte T. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542549.
  • 88
    Shaw BE,Mufti GJ,Mackinnon S,Cavenagh JD,Pearce RM,Towlson KE,Apperley JF,Chakraverty R,Craddock CF,Kazmi MA,Littlewood TJ,Milligan DW,Pagliuca A,Thomson KJ,Marks DI,Russell NH. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42: 783789.
  • 89
    Kantarjian H,Beran M,Cortes J,O'Brien S,Giles F,Pierce S,Shan J,Plunkett W,Keating M,Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006; 106: 10991109.
  • 90
    Barnard DR,Lange B,Alonzo TA,Buckley J,Kobrinsky JN,Gold S,Neudorf S,Sanders J,Burden L,Woods WG. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation. Blood 2002; 100: 427434.
  • 91
    Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Hematol 2000; 72: 139150.
  • 92
    Porter DL,Alyea EP,Antin JH,DeLima M,Estey E,Falkenburg JH,Hardy N,Kröger N,Leis J,Levine J,Maloney DG,Peggs K,Rowe JM,Wayne AS,Giralt S,Bishop MR,van Besien K. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the Committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 14671503.
  • 93
    Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol 2011; 38: 635647.
  • 94
    Sloand EM,Wu CO,Greenberg P,Young N,Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 25052511.
  • 95
    Passweg JR,Giagounidis AA,Simcock M,Aul C,Dobbelstein C,Stadler M,Ossenkoppele G,Hofmann WK,Schilling K,Tichelli A,Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. J Clin Oncol 2011; 29: 303309.